Cafizomide

PreclinicalSmall molecule

TThe First Affiliated Hospital of Soochow University

Cafizomide is one of 45 small molecule programs targeting Combination Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Combination TherapyNot yet recruiting

Combination TherapyPreclinical

Not yet recruiting

Competition

Competitive Landscape

56 competitors in Combination Therapy

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Approved

1 2

Ritalin

Novartis

Phase 3

1 3

Avastin

Roche

Phase 2

5 4

Liposomal Doxorubicin

Eli Lilly

Phase 3

1 5

Keytruda

Merck & Co.

Phase 2

3 6

Taxol

Teva

Phase 2

3 7

Beyfortus

BeiGene

Phase 2

3 8

Gleevec

Novartis

Phase 2

2 9

Braftovi

Pfizer

Phase 2

1 10

Cabometyx

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ANot yet recruiting

Combination Therapy

NCT07015021

Clinical

Trials by Indication[1]

Combination Therapy1 trial

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT07015021·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cafizomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cafizomide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cafizomide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe First Affiliated Hospital of Soochow University

Cafizomide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Combination Therapy1 trial

References

Drug Info

Quick Facts

Related News